Back to top
more

CVS Health (CVS)

(Delayed Data from NYSE)

$62.47 USD

62.47
11,378,135

+0.37 (0.60%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $62.49 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.

Zacks Equity Research

CVS Health (CVS) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

CVS Health (CVS) closed the most recent trading day at $61.96, moving 2.12% from the previous trading session.

Zacks Equity Research

Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings

by Zacks Equity Research

MOH's Q2 revenues are set to rise nearly 10%, but rising costs cloud its profit outlook.

Zacks Equity Research

Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?

by Zacks Equity Research

DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.

Zacks Equity Research

Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus

by Zacks Equity Research

Thermo Fisher eyes second-quarter 2025 growth with new tech launches in Analytical Instruments and Life-Science Solutions segments.

Moumi Mondal headshot

CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?

by Moumi Mondal

CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.

Zacks Equity Research

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Sumit Singh headshot

4 Value Stocks to Buy as Inflation and Market Volatility Rise

by Sumit Singh

CVS Health, Hudbay Minerals, Universal Health Services and ASB stand out as value stocks amid rising inflation.

Zacks Equity Research

CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Urmimala Biswas headshot

CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?

by Urmimala Biswas

CVS stock surges nearly 50% in 2025, aided by strong Q1 results, raised guidance and easing Medicare regulation risks.

Zacks Equity Research

Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?

by Zacks Equity Research

ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.

Zacks Equity Research

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Agenus (AGEN) and CVS Health (CVS) have performed compared to their sector so far this year.

Zacks Equity Research

ABT to Report Q2 Earnings: CGM and Cardiac Devices in Focus

by Zacks Equity Research

Abbott eyes Q2 growth with strong CGM momentum, cardiac device wins and resilient performance across key segments.

Zacks Equity Research

Here's Why You Should Add Cencora Stock to Your Portfolio Now

by Zacks Equity Research

COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.

Zacks Equity Research

Here's Why CVS Health (CVS) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

How to Find Strong Buy Medical Stocks Using the Zacks Rank

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.

Moumi Mondal headshot

Is CVS Moving Closer to Reaching Its Long-Term Low 3X Leverage Goal?

by Moumi Mondal

CVS Health inches closer to its long-term leverage target, helped by Aetna margin recovery and disciplined cash use.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Moumi Mondal headshot

Can CVS Sustain Pharmacy & Consumer Wellness Gains Through Year-End?

by Moumi Mondal

Strong pharmacy drug mix, flu season and store optimization power CVS Health's PCW gains. Will the momentum continue?

Zacks Equity Research

Zacks.com featured highlights include Hudbay Minerals, StoneCo, Centene and CVS Health

by Zacks Equity Research

HBM, STNE, CNC, and CVS stand out for low P/CF ratios and strong value scores as investors seek quality in a cautious market.

Zacks Equity Research

CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

CVS Health (CVS) closed at $66.6 in the latest trading session, marking a -4.28% move from the prior day.

Zacks Equity Research

Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sumit Singh headshot

4 Value Stocks to Invest in for the Second-Half 2025 Market Shift

by Sumit Singh

Hudbay, StoneCo, Centene, and CVS stand out as top value picks for H2 2025 with strong cash flow and growth prospects.

Zacks Equity Research

Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?